2-(4-Chlorophenyl)-2-methylaziridine | 1368715-84-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(4-Chlorophenyl)-2-methylaziridine
• 英文别名: 2-(4-chlorophenyl)-2-methylaziridine
• CAS: 1368715-84-7
• 化学式: C₉H₁₀ClN
• 分子量: 167.638
• InChiKey: OMLHJNUGDZXLEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(4-Chlorophenyl)-2-methylaziridine 在 4-二甲氨基吡啶 、 C₄₈H₃₉Cl₂F₆N₄O⁽¹⁺⁾*Br^(1-) 、 potassium carbonate 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 27.0h， 生成
  参考文献：
  名称：

  Asymmetric Substitution at the Tetrasubstituted Chiral Carbon: Catalytic Ring-Opening Alkylation of Racemic 2,2-Disubstituted Aziridines with 3-Substituted Oxindoles

  摘要：

  A highly diastereo- and enantioselective ring-opening alkylation of racemic 2,2-disubstituted aziridines with 3-substituted oxindoles is achieved under the catalysis of a chiral 1,2,3-triazolium salt. This reaction represents a hitherto unknown, catalytic stereoselective carbon carbon bond formation through direct substitution at the tetrasubstituted chiral carbon.

  DOI：

  10.1021/ja411647x
• 作为产物：
  描述：

  对氯甲基苯乙烯 在 氨 、 碘 作用下， 以 水 为溶剂， 反应 2.0h， 生成 2-(4-Chlorophenyl)-2-methylaziridine
  参考文献：
  名称：

  Asymmetric Substitution at the Tetrasubstituted Chiral Carbon: Catalytic Ring-Opening Alkylation of Racemic 2,2-Disubstituted Aziridines with 3-Substituted Oxindoles

  摘要：

  A highly diastereo- and enantioselective ring-opening alkylation of racemic 2,2-disubstituted aziridines with 3-substituted oxindoles is achieved under the catalysis of a chiral 1,2,3-triazolium salt. This reaction represents a hitherto unknown, catalytic stereoselective carbon carbon bond formation through direct substitution at the tetrasubstituted chiral carbon.

  DOI：

  10.1021/ja411647x

文献信息

• [EN] CARBONYL DERIVATIVES OF BETULIN<br/>[FR] DÉRIVÉS CARBONYLES DE BÉTULINE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013020245A1

  公开（公告）日：2013-02-14

  Disclosed are a compound characterized by the following formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof, wherein R3, L, and A are as described in the application. Said compounds are useful for the treatment of HIV.

  揭示了一种由以下化学式I或其药学上可接受的盐所表征的化合物，以及包含所述化合物或其药学上可接受的盐的药物组合物，其中R3、L和A如申请中所述。所述化合物对治疗HIV有用。
• PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
  申请人：Huang Taisheng

  公开号：US20110224190A1

  公开（公告）日：2011-09-15

  The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

  本发明提供了哌啶-4-基氮杂环丙烷衍生物，以及它们的组合物和使用方法，这些衍生物调节Janus激酶1（JAK1）的活性，并且在治疗与JAK1活性相关的疾病方面具有用处，例如炎症性疾病、自身免疫性疾病、癌症和其他疾病。
• ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES
  申请人：Herman Jean

  公开号：US20140088088A1

  公开（公告）日：2014-03-27

  The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of proliferative disorders and pathologic conditions such as, but not limited to, cancer such as leukemia.

  本发明涉及式I、II、III或IV的化合物，和/或其药用可接受的加合物盐和/或其立体异构体和/或其溶剂化合物，式(I)、(II)、(III)和(IV)中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求书中所定义或在发明说明书中详细描述的那样，以及使用所述化合物来治疗或预防增殖性疾病以及用于制造治疗或预防增殖性疾病的药物，特别是像白血病这样的癌症。本发明还涉及所述化合物的药物组合物以及使用所述药物组合物来治疗或预防增殖性疾病。本发明还涉及将所述化合物用作生物活性成分，更具体地用作治疗增殖性疾病和病理状况的药物，例如癌症如白血病等。
• [EN] SUBSTITUTED [1,2,4]TRIAZOLO[4,3-A]PYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS<br/>[FR] [1,2,4]TRIAZOLO[4,3-A]PYRIDINES SUBSTITUÉES, LEUR PRÉPARATION ET LEUR UTILISATION COMME MÉDICAMENTS
  申请人：NEOMED INST

  公开号：WO2017127930A1

  公开（公告）日：2017-08-03

  This application relates to substituted [1,2,4]triazolo[4,3-a]pyridines of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted [1,2,4]triazolo[4,3-a]pyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers. (Formula (I))

  该应用涉及式(I)的取代[1,2,4]三唑并[4,3-a]吡啶，包括它们的组合物以及它们在治疗需要抑制溴结构域的疾病和症状中的用途。例如，该应用涉及取代[1,2,4]三唑并[4,3-a]吡啶及其用作溴结构域抑制剂的用途。本申请还涉及治疗或预防增生性疾病、自身免疫性疾病、炎症性疾病、皮肤疾病和肿瘤，包括肿瘤和/或癌症。
• HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS
  申请人：Takahashi Akira

  公开号：US20120065189A1

  公开（公告）日：2012-03-15

  The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R 1 and R 2 , each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R 3 represents a lower alkynyl group or the like; R 4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.

  本发明提供了一种新型杂环化合物。所述杂环化合物的通式（1）表示，其中，R1和R2各自独立地表示氢；苯基低烷基，其可以在苯环上和/或低烷基上具有选自低烷基等的取代基；或环状C3-C8烷基低烷基；或类似物；R3表示低炔基或类似物；R4表示苯基，其可以具有选自1,3,4-噁二唑基（例如，卤素）或选自吡啶基等杂环基的取代基；所述杂环基可以具有至少一个选自低烷氧基等的取代基或其盐。